📣 VC round data is live. Check it out!
- Public Comps
- Black Diamond Therapeutics
Black Diamond Therapeutics Valuation Multiples
Discover Black Diamond Therapeutics' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Fractyl Health, Outlook Therapeutics, XSpray Pharma, Faron Pharmaceuticals and more.
Black Diamond Therapeutics Overview
About Black Diamond Therapeutics
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Founded
2016
HQ

Employees
24
Website
Financials (LTM)
EV
$25M
Valuation Multiples
Start free trialBlack Diamond Therapeutics Financials
Black Diamond Therapeutics reported last 12-month revenue of $43M and negative EBITDA of ($11M).
In the same LTM period, Black Diamond Therapeutics generated $43M in gross profit, ($11M) in EBITDA losses, and had net loss of ($4M).
Revenue (LTM)
Black Diamond Therapeutics P&L
In the most recent fiscal year, Black Diamond Therapeutics reported revenue of $70M and EBITDA of $20M.
Black Diamond Therapeutics is profitable as of last fiscal year, with EBITDA margin of 29% and net margin of 32%.
Financial data powered by Morningstar, Inc.
Black Diamond Therapeutics Stock Performance
Black Diamond Therapeutics has current market cap of $125M, and enterprise value of $25M.
Market Cap Evolution
Black Diamond Therapeutics' stock price is $2.18.
Black Diamond Therapeutics share price decreased by 1.8% in the last 30 days, and by 12.1% in the last year.
Black Diamond Therapeutics has an EPS (earnings per share) of $0.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25M | $125M | -4.0% | -1.8% | 2.3% | -12.1% | $0.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBlack Diamond Therapeutics Valuation Multiples
Black Diamond Therapeutics trades at 0.6x EV/Revenue multiple, and (2.2x) EV/EBITDA.
EV / Revenue (LTM)
Black Diamond Therapeutics Financial Valuation Multiples
As of June 3, 2026, Black Diamond Therapeutics has market cap of $125M and EV of $25M.
Black Diamond Therapeutics has a P/E ratio of (31.7x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Black Diamond Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Black Diamond Therapeutics Margins & Growth Rates
Black Diamond Therapeutics decreased revenue by 90% and EBITDA by 332% in the last fiscal year.
In the most recent fiscal year, Black Diamond Therapeutics reported EBITDA margin of 29% and net margin of 32%.
Black Diamond Therapeutics Margins
Black Diamond Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Black Diamond Therapeutics Operational KPIs
Black Diamond Therapeutics' revenue per employee in the last FY averaged $2.9M, while opex per employee averaged $2.1M for the same period.
Black Diamond Therapeutics' Rule of 40 is (747%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Black Diamond Therapeutics' Rule of X is (881%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Black Diamond Therapeutics Competitors
Black Diamond Therapeutics competitors include Fractyl Health, Outlook Therapeutics, XSpray Pharma, Faron Pharmaceuticals, Bioxyne, Orient Europharma Co, Naturland Holding, Cognition Therapeutics, vTv Therapeutics and NeOnc.
Most Black Diamond Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | (1.3x) | (1.4x) | |||
| 101.5x | 12.7x | (2.3x) | - | |||
| 176.1x | 26.8x | (7.9x) | (5.9x) | |||
| 364.0x | 629.7x | (6.0x) | (5.8x) | |||
| 6.0x | - | 37.7x | - | |||
| 1.1x | - | (4375.9x) | - | |||
| 6.4x | - | 22.1x | - | |||
| - | - | (3.8x) | - | |||
This data is available for Pro users. Sign up to see all Black Diamond Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Black Diamond Therapeutics VC Funding History
Before going public, Black Diamond Therapeutics raised $197M in total equity funding, across 4 rounds.
Black Diamond Therapeutics Funding Rounds
Investments by Black Diamond Therapeutics
Black Diamond Therapeutics has invested in 1 company to date.
Latest investment by Black Diamond Therapeutics was on December 12th 2022. Black Diamond Therapeutics invested in Launchpad Therapeutics in their $30M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by Black Diamond Therapeutics
| Description | Launchpad Therapeutics is a Boston-based biotechnology firm specializing in precision oncology through engineered antibodies. The company develops T cell engager antibodies targeting solid tumors, including platforms for conditional activation to minimize toxicity. Founded in 2021, it raised Series A funding from investors like ARCH Venture Partners and Takeda Ventures. Launchpad Therapeutics advances candidates like LP-284 into clinical trials for difficult-to-treat cancers such as pancreatic and colorectal. |
| HQ Country | |
| HQ City | San Francisco, CA |
| Deal Date | 12 Dec 2022 |
| Round | Series A |
| Raised | $30M |
| Investors | Black Diamond Therapeutics; New Enterprise Associates; Versant Ventures |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Black Diamond Therapeutics investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Black Diamond Therapeutics
| When was Black Diamond Therapeutics founded? | Black Diamond Therapeutics was founded in 2016. |
| Where is Black Diamond Therapeutics headquartered? | Black Diamond Therapeutics is headquartered in United States. |
| How many employees does Black Diamond Therapeutics have? | As of today, Black Diamond Therapeutics has over 24 employees. |
| Who is the CEO of Black Diamond Therapeutics? | Black Diamond Therapeutics' CEO is Mark A. Velleca. |
| Is Black Diamond Therapeutics publicly listed? | Yes, Black Diamond Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Black Diamond Therapeutics? | Black Diamond Therapeutics trades under BDTX ticker. |
| When did Black Diamond Therapeutics go public? | Black Diamond Therapeutics went public in 2020. |
| Who are competitors of Black Diamond Therapeutics? | Black Diamond Therapeutics main competitors include Fractyl Health, Outlook Therapeutics, XSpray Pharma, Faron Pharmaceuticals, Bioxyne, Orient Europharma Co, Naturland Holding, Cognition Therapeutics, vTv Therapeutics, NeOnc. |
| What is the current market cap of Black Diamond Therapeutics? | Black Diamond Therapeutics' current market cap is $125M. |
| What is the current revenue of Black Diamond Therapeutics? | Black Diamond Therapeutics' last 12 months revenue is $43M. |
| What is the current revenue growth of Black Diamond Therapeutics? | Black Diamond Therapeutics revenue growth (NTM/LTM) is (91%). |
| What is the current EV/Revenue multiple of Black Diamond Therapeutics? | Current revenue multiple of Black Diamond Therapeutics is 0.6x. |
| Is Black Diamond Therapeutics profitable? | No, Black Diamond Therapeutics is not profitable. |
| What is the current EBITDA of Black Diamond Therapeutics? | Black Diamond Therapeutics has negative EBITDA and is not profitable. |
| What is Black Diamond Therapeutics' EBITDA margin? | Black Diamond Therapeutics' last 12 months EBITDA margin is (25%). |
| What is the current EV/EBITDA multiple of Black Diamond Therapeutics? | Current EBITDA multiple of Black Diamond Therapeutics is (2.2x). |
| How many companies Black Diamond Therapeutics has acquired to date? | Black Diamond Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Black Diamond Therapeutics has invested to date? | As of June 2026, Black Diamond Therapeutics has invested in 1 company. |
| What was the last Black Diamond Therapeutics investment? | On 12th December 2022 Black Diamond Therapeutics invested in Launchpad Therapeutics, participating in a $30M Series A round, alongside New Enterprise Associates and Versant Ventures. |
| In what companies Black Diamond Therapeutics invested in? | Black Diamond Therapeutics invested in Launchpad Therapeutics. |
See public comps similar to Black Diamond Therapeutics
Lists including Black Diamond Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
